Valuation: Fulgent Genetics, Inc.

Market Cap 552M 484M 446M 418M 783M 52.08B 800M 5.36B 2.08B 25.74B 2.07B 2.03B 89.25B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 552M 484M 446M 418M 783M 52.08B 800M 5.36B 2.08B 25.74B 2.07B 2.03B 89.25B EV / Sales 2026 *
1.57x
EV / Sales 2027 * 1.37x
Free-Float
52.26%
Yield 2026 *
-
Yield 2027 * -
1 day+1.00%
1 week+9.47%
Current month+7.66%
1 month+10.53%
3 months+19.30%
6 months-26.91%
Current year-25.66%
1 week 17.74
Extreme 17.74
19.71
1 month 17.4
Extreme 17.4
19.93
Current year 13.46
Extreme 13.46
28.95
1 year 13.46
Extreme 13.46
31.04
3 years 13.46
Extreme 13.46
44.09
5 years 13.46
Extreme 13.46
112
10 years 2.72
Extreme 2.725
189.89
Manager TitleAgeSince
President 59 2022-05-02
Chief Executive Officer 70 2016-05-12
Director of Finance/CFO 58 2015-12-31
Director TitleAgeSince
Chairman 70 2016-08-31
Director/Board Member 76 2019-07-31
Director/Board Member 57 2022-07-31
Date Insider Type Main position Quantity % Market Cap.
06-01Sell

Founder

-2,146 0.0070%
06-01Sell

Chief Technology Officer

-1,688 0.0055%
05-31Tax

Chief Executive Officer

-4,392 0.0143%
Change 5-day change 1-year change 3-year change Capi.($)
+1.90%+9.47%-0.36%-47.44% 552M
+1.02%+14.90%+56.32%+427.34% 37.34B
+1.51%+5.46%+4.41%+13.61% 21.84B
-0.78%+2.92%-21.91%-41.22% 7.04B
+3.37%+7.03%+2.81%+82.17% 4.72B
+1.76%+1.58%+22.09%+60.13% 2.99B
+2.65%+25.56%-22.33%+1,093.57% 2.04B
-4.74%+3.56%+29.74%-27.79% 1.78B
+3.53%+24.02%+93.99%-14.42% 1.79B
-6.73%-9.88%-22.08%-69.93% 1.62B
Average -0.56%+6.62%+14.27%+147.60% 8.17B
Weighted average by Cap. +0.29%+8.54%+27.71%+226.99%

Financials

2026 *2027 *
Net sales 352M 309M 285M 266M 500M 33.22B 510M 3.42B 1.32B 16.42B 1.32B 1.29B 56.94B 402M 352M 325M 304M 570M 37.89B 582M 3.9B 1.51B 18.73B 1.51B 1.48B 64.94B
Net income -90M -78.91M -72.74M -68.1M -128M -8.49B -130M -874M -338M -4.2B -338M -331M -14.55B -73M -64.01M -59M -55.24M -104M -6.89B -106M -709M -274M -3.4B -274M -268M -11.8B
Net Debt - -
Logo Fulgent Genetics, Inc.
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
Employees
1,315
Date Price Change Volume
26-06-26 US$19.57 +0.67% 136,246
26-06-25 US$19.44 +1.62% 252,326
26-06-24 US$19.13 +5.23% 266,264
26-06-23 US$18.18 +1.91% 255,648
26-06-22 US$17.84 -0.89% 348,151
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
19.44USD
Average target price
15.00USD
Spread / Average Target
-22.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FLGT Stock